A new SHV-derived extended-spectrum beta-lactamase (SHV-24) that hydrolyzes ceftazidime through a single-amino-acid substitution (D179G) in the -loop. 2000

H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
Department of Bacterial and Blood Products, National Institute of Infectious Diseases, Tokyo, Japan.

A new SHV-derived extended-spectrum beta-lactamase (SHV-24) conferring high-level resistance to ceftazidime but not cefotaxime and cefazolin was identified in Japan. This enzyme was encoded by a transferable 150-kb plasmid from an Escherichia coli clinical isolate. The pI and K(m) for CAZ of this enzyme were 7.5 and 30 microM, respectively. SHV-24 was found to have a D179G substitution in the Omega-loop of the enzyme.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001618 beta-Lactamases Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins. beta-Lactamase,beta Lactamase,beta Lactamases
D019943 Amino Acid Substitution The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties. Amino Acid Substitutions,Substitution, Amino Acid,Substitutions, Amino Acid

Related Publications

H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
December 2001, Antimicrobial agents and chemotherapy,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
February 2005, Antimicrobial agents and chemotherapy,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
August 2006, The Journal of antimicrobial chemotherapy,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
June 1989, Antimicrobial agents and chemotherapy,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
April 1988, FEBS letters,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
May 1999, Antimicrobial agents and chemotherapy,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
May 2011, Antimicrobial agents and chemotherapy,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
June 1991, FEMS microbiology letters,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
July 1997, FEMS microbiology letters,
H Kurokawa, and T Yagi, and N Shibata, and K Shibayama, and K Kamachi, and Y Arakawa
November 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Copied contents to your clipboard!